Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Kardiatonos shines spotlight on new Dx and Tx
January 2017
SHARING OPTIONS:

ROCHESTER, Mich.—Biopharmaceutical company Kardiatonos Inc. has launched a new website to educate the public, financial and medical communities on its pipeline and business efforts. Among those is KardiaKalyx, the company’s upcoming diagnostic, and its preclinical therapeutic Thrombex, which is comprised of proprietary compounds designed to target the root of atherosclerosis and cardiovascular disease (CVD) by focusing on the endothelial glycocalyx. Kardiatonos hopes to make commercially available the first CVD diagnostic test that can enable physicians to determine the amount of CVD in a patient from a blood test, with the intent of commercializing its biomarker test via licensing agreements with strategic partners.
 
“Both of our products are unique, and represent exciting opportunities in the global marketplace,” said Dr. Kenneth I. Kohn, director and CEO of Kardiatonos, adding that “Our intellectual property provides our company with a pipeline of potential new therapies and diagnostics that show great promise in addressing other chronic diseases.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.